Project Number 5P50AG016573-15 Agency/Funding Organization NIA Funding Year 2014 View Full Project Details for ADMINISTRATIVE CORE Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category F. Research Resources 1. Alzheimer's Disease Centers Researcher and Organization Principal Investigator COTMAN, CARL WAYNE Principal Investigator First Name CARL WAYNE Principal Investigator Last Name COTMAN Awardee Organization UNIVERSITY OF CALIFORNIA IRVINE Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-AG-10-002: ALZHEIMER'S DISEASE RESEARCH CENTERS (P50) FY Overall Cost $239,410 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PHELPS, CREIGHTON H. Related Resources Repository [AlzPED] MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice [AlzPED] Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease. [AlzPED] Human Neural Stem Cells Improve Cognition and Promote Synaptic Growth in Two Complementary Transgenic Models of Alzheimer’s Disease and Neuronal Loss [AlzPED] Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. [AlzPED] Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial [AlzPED] Low Concentrations of Anti-Abeta Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology [AlzPED] Reductions in Aβ-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation [AlzPED] Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. Pagination Previous page ‹‹ Page 2
